mAb vs Bispecific vs ADC Manufacturing: Format, Cost and Yield Compared
Standard mAb manufacturing is the mature, cheap, high-titer baseline (5–8 g/L CHO fed-batch, $20–150/g COGS, 100+ approvals). Choose a bispecific only when the biology genuinely requires dual epitope engagement — you pay a 2–5× per-gram premium for a mechanism no mAb can deliver. Choose an ADC when you need a targeted cytotoxin: same mAb backbone plus a $500–780/g bioconjugation step dominated by the drug-linker at $200–4,000/g raw material. bsAb yield is limited by chain mispairing; ADC yield is limited by DAR distribution control.
Key differences at a glance
- Monoclonal antibody: symmetric IgG, 5–8 g/L CHO fed-batch, 70–75% downstream yield, ~$20–150/g COGS, 100+ FDA approvals. The mature default.
- Bispecific antibody: asymmetric heterodimer, 1–2 g/L stable CHO (up to 5 g/L optimised), 40–60% downstream yield, ~$100–500/g COGS, ~15 approvals. Mispairing is the yield killer.
- ADC: mAb + chemical conjugation, DAR target 3–4 (or 8 for site-specific), $499–778/g total COGS, 14 approvals. Drug-linker raw material dominates cost at $200–4,000/g.
- Best for lowest cost of goods: mAb by 5–20× per gram.
- Best for a mechanism no mAb can deliver: bispecific (T-cell engagers, dual checkpoints, receptor bridging) or ADC (targeted cytotoxin).
Side-by-side comparison
| Factor | Monoclonal antibody | Bispecific antibody | Antibody-drug conjugate |
|---|---|---|---|
| Molecular structure | Symmetric IgG (2H + 2L) | Asymmetric heterodimer (2H + 1–2L) | mAb + covalent drug-linker payload |
| Typical CHO titer | 5–10 g/L (up to 15 g/L) | 1–2 g/L (up to 5 g/L optimised) | Same as parent mAb (5–8 g/L) |
| Downstream yield | 70–75% | 40–60% (mispair removal) | 50–65% (mAb) then 60–80% (conjugation) |
| Downstream complexity | Protein A + 2 polish | Protein A + 3 polish (HIC/CEX/MMC) | mAb train + reduce + conjugate + HIC DAR polish |
| Cell-line development time | 10–12 weeks | 12–16 weeks (balanced chain selection) | Same as mAb + 3–6 months conjugation PD |
| Typical COGS per gram | $20–150/g | $100–500/g (2–5× mAb) | $499–778/g (drug-linker dominated) |
| Facility BSL / containment | BSL-1 / OEB 1–2 | BSL-1 / OEB 1–2 | OEB 4–5 conjugation suite (high-potency) |
| Key manufacturing risk | Aggregation, HCP clearance | Chain mispairing, homodimer contamination | DAR distribution, free drug, aggregation |
| Approved products (FDA, 2026) | 100+ | ~15 | 14 |
| Modality growth rate | Mature (biosimilar pressure) | Rapid (immuno-oncology, autoimmune) | Rapid (targeted oncology) |
Titer and yield ranges reflect published CHO fed-batch platform data. Your vendor's current process economics take precedence. See the biopharmaceutical cost-of-goods guide and the Fermentation Economics Calculator for parameter-level modelling.
Monoclonal antibodies in detail
A monoclonal antibody is a symmetric IgG made from two identical heavy chains and two identical light chains that assemble into a single Y-shaped molecule with a molecular weight of roughly 150 kDa. Modern therapeutic mAbs are produced almost exclusively in Chinese hamster ovary (CHO) suspension cells, engineered for high specific productivity, human-like N-glycosylation, and stable single-copy transgene integration. The FDA has approved more than 100 monoclonal antibody therapeutics (roughly 130+ including biosimilars), spanning oncology (Herceptin, Rituxan, Keytruda, Opdivo), autoimmune (Humira, Remicade, Stelara), infectious disease, cardiovascular, and ophthalmology. The upstream and downstream unit operations are the reference architecture that both bispecific and ADC platforms build on.
How it works
Upstream, a fed-batch culture in a 2,000–20,000 L single-use or stainless steel bioreactor runs 12–16 days at 36.5 °C, with programmed nutrient feeds and a temperature shift to 32–33 °C around day 6 to slow growth and push specific productivity. Modern CHO platforms from Lonza GS Xceed, Thermo Fisher CHO-S, Horizon Discovery (Revvity) CHOZN and CHO-DG44, and Selexis SURE CHO-M deliver 5–10 g/L final titer in a mature stable pool. Downstream is the "platform" mAb train: primary recovery (depth filtration or disc-stack centrifugation), Protein A capture, low-pH viral inactivation, cation-exchange bind-elute or flow-through, anion-exchange flow-through polish, nanofiltration for viral clearance, and ultrafiltration/diafiltration. Overall downstream yield sits at 70–75%. Vendors like Cytiva (MabSelect PrismA), JSR (Amsphere A3), and Tosoh Bioscience (Toyopearl AF-rProtein A) compete on dynamic binding capacity, alkaline stability, and lifetime — decisions that drive per-gram cost of goods.
When mAb wins
Standard mAbs win whenever a single target-engagement mechanism (antagonism, agonism, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, receptor blockade) achieves the intended biology. They dominate on regulatory precedent (well-mapped IND to BLA path), commercial CDMO capacity from Lonza, Samsung Biologics, WuXi Biologics, and Boehringer Ingelheim BioXcellence, biosimilar-driven downward pressure on COGS to $20–50/g at 10,000+ L scale, and the ability to run large-population indications (chronic autoimmune, oncology maintenance) economically. Adalimumab (Humira) at a peak revenue of $20B+ demonstrates the ceiling of the format.
Bispecific antibodies in detail
A bispecific antibody is an engineered molecule that binds two different epitopes with two distinct antigen-binding domains. Approximately 15 bispecific antibodies have received FDA approval as of mid-2026: Amgen Blincyto (blinatumomab), Roche Hemlibra (emicizumab), J&J Rybrevant (amivantamab), Immunocore Kimmtrak (tebentafusp), Roche Vabysmo (faricimab), Lunsumio (mosunetuzumab), Tecvayli (teclistamab), Talvey (talquetamab), Elrexfio (elranatamab), Columvi (glofitamab), Epkinly (epcoritamab), Imdelltra (tarlatamab), Ziihera (zanidatamab), and Bizengri (zenocutuzumab). The dominant clinical applications are T-cell engagers that crosslink CD3 with a tumour antigen (BiTEs, DuoBody, XmAb bispecifics), dual-checkpoint blockade (PD-1 × LAG-3, PD-1 × VEGF), and receptor bridging (Hemlibra bridges Factor IX and Factor X to mimic Factor VIII in hemophilia A).
How it works
The core manufacturing problem is chain assembly. Four different polypeptide chains can be combined in 16 possible ways, only two of which (~12.5%) give the desired asymmetric heterodimer. Format engineering solves this in one of several ways: knobs-into-holes Fc heterodimerization (Roche/Genentech, invented in the mid-1990s) engineers a "knob" mutation in one heavy chain CH3 and a complementary "hole" in the other; Roche CrossMab swaps the CH1 and CL domains in one Fab arm to prevent light-chain mispairing; Genmab DuoBody uses controlled Fab-arm exchange between two separately expressed IgGs; Xencor XmAb combines charge-pair mutations with knobs-into-holes; and common-light-chain platforms select for a single shared light chain that pairs correctly with both heavy chains. CDMO platform technologies include WuXi Biologics WuXiBody and Lonza bYlok. Titer typically lands at 0.6–2.2 g/L in stable CHO pools; Gong and Wu (2023, Antibody Therapeutics) demonstrated ~5 g/L for a Fabs-in-tandem IgG by optimising the transfection ratio of the two heavy chains. Downstream needs an extra 1–2 chromatography steps beyond the standard mAb polish to strip homodimers, mispaired species, and half-molecules — differential Protein A elution, HIC, mixed-mode resins, or cation-exchange in bind-and-elute mode.
When bispecific wins
Bispecific antibodies win when the biology genuinely requires simultaneously engaging two epitopes. T-cell engagers are the largest clinical category: teclistamab (Tecvayli, BCMA × CD3) and elranatamab (Elrexfio, BCMA × CD3) in multiple myeloma, epcoritamab (Epkinly, CD20 × CD3) and glofitamab (Columvi, CD20 × CD3) in DLBCL, tarlatamab (Imdelltra, DLL3 × CD3) in small-cell lung cancer, and mosunetuzumab (Lunsumio, CD20 × CD3) in follicular lymphoma. Non-T-cell-engager wins include Vabysmo (VEGF-A × Ang-2) in wet AMD, Rybrevant (EGFR × MET) in EGFR-mutant NSCLC, and Hemlibra (FIX × FX) in hemophilia A. Bispecifics accept a 2–5× per-gram cost premium over standard mAb because the format is what unlocks the mechanism.
Antibody-drug conjugates in detail
An antibody-drug conjugate is a mAb (or occasionally a bispecific) covalently linked to a cytotoxic payload via a chemical linker. The FDA has approved 14 ADCs as of mid-2026, dominated by four toxin classes: auristatins (MMAE, MMAF used in Adcetris, Padcev, Polivy, Tivdak, Blenrep, Emrelis), maytansinoids (DM1 in Kadcyla, DM4 in Elahere), calicheamicins (Mylotarg, Besponsa), pyrrolobenzodiazepine (PBD, in Zynlonta), and topoisomerase-I inhibitors (deruxtecan/DXd in Enhertu and Datroway, SN-38 in Trodelvy). Enhertu (trastuzumab deruxtecan) leads the category at ~$3.75B in 2024 revenue, followed by Adcetris (~$1.9B), Padcev (~$1.6B), and Trodelvy (~$1.3B).
How it works
ADC manufacturing has two independent halves. First, the naked mAb intermediate is produced with the same CHO fed-batch and Protein A downstream train as any therapeutic monoclonal — typical CDMO price for a GMP mAb intermediate suitable for conjugation is ~$300/g. Second, the mAb undergoes bioconjugation in a dedicated conjugation suite (OEB 4–5 containment, high-potency): for interchain cysteine conjugation (Adcetris, Kadcyla, Padcev) the four interchain disulfides are partially reduced with TCEP to expose 4 or 8 free thiols per mAb, then reacted with a maleimide-capped drug-linker in aqueous buffer at 4–25 °C; for site-specific engineered platforms (Enhertu, Trodelvy, Datroway) the antibody has engineered cysteines or unnatural amino acids at defined positions that permit higher-purity DAR 8 species. The reaction is quenched, excess drug-linker is removed by tangential-flow filtration or size-exclusion, and DAR distribution is polished by hydrophobic interaction chromatography (HIC) or ceramic hydroxyapatite. DAR characterisation uses reversed-phase HPLC and native mass spectrometry. Independent cost-of-goods models (Biopharm Services, 2018) put the total ADC COGS at $499.70/g in an integrated mAb + conjugation facility and $777.50/g in a dedicated conjugation-only facility, with drug-linker raw material at $200–$2,000/g the dominant cost driver.
When ADC wins
ADCs win when the tumour target is well-validated for internalisation (HER2, TROP2, Nectin-4, folate receptor alpha, BCMA, CD22, CD33, CD30) and the naked mAb has no direct-kill mechanism against the tumour phenotype. The therapeutic thesis is that a targeted cytotoxin delivers a lethal payload dose selectively to antigen-positive cells while sparing systemic exposure. The commercial market rewards this — Enhertu alone has expanded its label across HER2-positive breast, gastric, and lung cancers, and HER2-low breast cancer. CDMO capacity from Lonza Bioconjugates, WuXi Biologics ADC, Abzena, Piramal Pharma Solutions, and Sartorius (formerly Polyplus) is expanding fast, though the OEB 4–5 containment requirement means dedicated conjugation suites are capital-intensive and lead times can stretch to 12–18 months for a new facility slot.
Pros and cons
Monoclonal antibody
Advantages
- Mature platform: 100+ FDA approvals, well-mapped IND-to-BLA path, extensive biosimilar precedent.
- Highest titer and lowest per-gram COGS: 5–10 g/L fed-batch, $20–150/g at commercial scale.
- Plug-in downstream: platform Protein A + 2 polish + UFDF applies to almost any IgG.
- Largest CDMO capacity pool: Lonza, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim, Catalent, Fujifilm Diosynth are all bookable in months.
Disadvantages
- Single mechanism of action — cannot bridge two epitopes or deliver a cytotoxin.
- Biosimilar erosion after loss-of-exclusivity compresses revenue (Humira, Rituxan, Herceptin).
- Direct-kill activity is weak against solid tumours without payload delivery.
- High-dose subcutaneous formats need high-concentration formulation development to hit under 2 mL injection volumes.
Bispecific antibody
Advantages
- Unlocks mechanisms no mAb can deliver: T-cell engagement, dual-checkpoint blockade, receptor bridging.
- Off-the-shelf inventory: unlike CAR-T, no patient-specific manufacturing wait.
- Rapid growth category: ~15 approvals in the last 10 years, immuno-oncology and autoimmune pipelines expanding.
- Reusable IgG-like production infrastructure (fill-finish, cold chain).
Disadvantages
- Chain mispairing caps stable-pool titer at 1–2 g/L versus 5–8 g/L for mAb; 2–5× per-gram COGS.
- Extra downstream polishing steps to strip homodimers, mispaired species, and half-molecules.
- Cytokine release syndrome risk for T-cell engagers requires step-up dosing schemes and REMS.
- Format IP is fragmented across knobs-into-holes, CrossMab, DuoBody, XmAb — licensing negotiations add cycle time.
Antibody-drug conjugate
Advantages
- Delivers a cytotoxic dose selectively to antigen-positive cells: Enhertu label expansions demonstrate the commercial ceiling.
- Reuses the standard mAb upstream and Protein A capture — the conjugation step bolts on downstream.
- Fastest-growing modality in oncology by product count and revenue.
- Site-specific conjugation platforms (engineered cysteine, unnatural amino acid, glycan-engineering) enable narrow DAR 8 species with up to 80% homogeneity.
Disadvantages
- OEB 4–5 conjugation suite is capex-intensive; CDMO capacity constrained with 12–18 month lead times.
- Drug-linker raw material dominates COGS at $200–$4,000/g; total ADC COGS ~$500–780/g.
- DAR distribution and free-drug residuals require dedicated in-process analytics (RP-HPLC, native MS, LC-MS free drug).
- Payload safety and containment discipline required across manufacturing, sampling, and shipping.
Which format should you choose?
Pick based on the dominant constraint: mechanism required, target-population size, and cost of goods ceiling.
Large-population chronic indication
Autoimmune (Humira class), oncology maintenance, ophthalmology, cardiovascular. Per-gram COGS dominates programme economics at 100+ mg/kg cumulative dosing.
Choose mAbMechanism needs two epitopes at once
T-cell engagement (BCMA × CD3, CD20 × CD3), dual checkpoint (PD-1 × LAG-3, PD-1 × VEGF), receptor bridging (Hemlibra). No mAb can deliver this biology.
Choose BispecificTargeted cytotoxin for solid tumour
Well-validated internalising target (HER2, TROP2, Nectin-4, FRα), naked mAb has weak direct kill, dose window supports $500–780/g COGS at 5–20 mg/kg.
Choose ADCFirst programme — no established platform
Cheapest capex, largest CDMO capacity, deepest regulatory precedent. Start with mAb unless the mechanism specifically forces you off the format.
Choose mAbReal-world use cases
Approved products illustrate why the industry has converged on each format for specific problems.
Humira (adalimumab) at 10,000+ L scale
AbbVie's Humira peaked at $20B+ annual revenue on the strength of the mAb platform's per-gram economics. Now under biosimilar pressure from 10+ approved biosimilars; the format itself is what enabled the scale-out.
Tecvayli (teclistamab) — J&J
The first BCMA × CD3 T-cell engager approved for multiple myeloma. Off-the-shelf alternative to autologous BCMA CAR-T (Carvykti) at a fraction of the vein-to-vein time and lower per-episode cost.
Hemlibra (emicizumab) — Roche
A non-oncology bispecific: bridges Factor IX and Factor X to substitute for missing Factor VIII in hemophilia A. Subcutaneous, monthly dosing. The classic example of a mechanism no mAb can deliver.
Enhertu (trastuzumab deruxtecan) — Daiichi/AZ
DAR 8 deruxtecan payload with a cleavable linker. Expanded from HER2+ breast into HER2-low, gastric, NSCLC. ~$3.75B 2024 revenue and the reference commercial-scale site-specific ADC.
Modelling per-gram COGS across formats?
The Fermentation Economics Calculator estimates cost of goods for CHO fed-batch mAb and bispecific runs by titer, downstream yield, and batch count. Combine with the biopharmaceutical COGS guide to sanity-check per-gram economics before locking a platform decision.
Open the Fermentation Economics CalculatorCost and lifecycle considerations
mAb COGS is dominated by fixed facility overhead and consumables amortised across large fed-batch runs. Bispecific COGS is dominated by low titer and extra downstream yield loss from mispair removal. ADC COGS is dominated by drug-linker raw material at $200–$4,000/g. Optimising the wrong lever wastes engineering effort.
Standard mAb manufacturing at commercial scale (10,000–15,000 L bioreactors, 5–8 g/L fed-batch, mature downstream) sits at $20–150 per gram cost of goods sold. Continuous mAb bioprocessing benchmarks around $51/g against $99/g for fed-batch in published economic analyses. The Bill & Melinda Gates Foundation and LifeArc have publicly targeted a $10/g platform for global-health mAbs — the theoretical floor for the format.
Bispecific antibodies typically run 2–5× the per-gram COGS of a standard mAb. The dominant drivers are lower titer (1–2 g/L versus 5–8 g/L, halving the mass produced per batch), extra downstream polishing to remove mispaired species and homodimers (each additional column adds yield loss and buffer consumption), and smaller batch sizes reflecting the earlier commercial stage of the modality. As bispecific titers improve toward 5 g/L in optimised platforms, per-gram economics will compress toward the mAb baseline.
ADC total cost of goods sits at $499.70/g in an integrated mAb + conjugation facility and $777.50/g in a dedicated conjugation-only facility that buys the mAb intermediate at ~$300/g (Biopharm Services, 2018 cost model). The drug-linker raw material is the dominant cost driver at $200–$4,000/g depending on toxin class — auristatins (MMAE, MMAF) at the lower end, deruxtecan and pyrrolobenzodiazepines at the higher end. Yield in the conjugation step itself is typically 60–80%, and DAR polishing on HIC adds another 5–15% yield loss.
| Cost component | Monoclonal antibody | Bispecific antibody | Antibody-drug conjugate |
|---|---|---|---|
| CHO fed-batch upstream | ~$5–15/g | ~$20–60/g | ~$5–15/g (mAb intermediate) |
| Protein A + polish downstream | ~$10–30/g | ~$40–120/g | ~$10–30/g (mAb intermediate) |
| Drug-linker raw material | N/A | N/A | ~$200–2,000/g of ADC |
| Conjugation + DAR polish | N/A | N/A | ~$100–200/g of ADC |
| QC and release testing | ~$5–20/g | ~$15–50/g | ~$20–60/g |
| Facility overhead per gram | ~$5–50/g | ~$20–200/g | ~$50–200/g (OEB 4–5) |
| Total COGS per gram | ~$20–150/g | ~$100–500/g | ~$499–778/g |
Vendor landscape
Major commercial CHO platforms, CDMOs, and bioconjugation specialists in each format.
Monoclonal antibody platforms and CDMOs
- Lonza GS Xceed: glutamine synthetase-based CHO platform, widely licensed for commercial mAbs; integrated with Lonza CDMO capacity in Portsmouth, Slough, and Visp.
- Samsung Biologics: world's third-largest biologics CDMO by capacity; Songdo Plants 1–5 total ~784,000 L, dedicated stainless-steel mAb capacity.
- WuXi Biologics: global CDMO with mAb, bispecific, and ADC platform technologies (WuXiBody, WuXi XDC for ADC).
- Boehringer Ingelheim BioXcellence: full-service mAb CDMO with commercial mammalian and microbial capacity in Biberach and Vienna.
- Fujifilm Diosynth Biotechnologies: Apollo X CHO platform and mAb CDMO capacity across Hillerød, Research Triangle Park, and Teesside.
- Selexis (JSR) SURE CHO-M: stable pool cell-line development licensed by many mAb developers as an alternative to Lonza GS.
Bispecific antibody platforms and CDMOs
- WuXi Biologics WuXiBody: proprietary bispecific format that simplifies mAb-like expression, purification, and formulation.
- Lonza bYlok: Fc heterodimerization plus light-chain pairing technology designed to solve mispairing in bispecifics.
- Roche CrossMab: CH1/CL crossover format that forces correct light-chain pairing; behind Vabysmo, Lunsumio, Columvi.
- Genmab DuoBody: controlled Fab-arm exchange platform; behind Epkinly (with AbbVie), Rybrevant (with J&J), and Tepkinly.
- Xencor XmAb: charge-pair + knobs-into-holes bispecific format; Talvey (with J&J), Plamotamab, and Vudalimab.
- Amgen BiTE: tandem-scFv T-cell-engager format; Blincyto (first approved) and multiple pipeline candidates.
ADC bioconjugation CDMOs
- Lonza Bioconjugates: integrated mAb + bioconjugation capacity in Visp, Switzerland; supports auristatin, maytansinoid, and site-specific chemistries.
- WuXi Biologics ADC / WuXi XDC: end-to-end mAb intermediate plus conjugation and analytical development; expanded capacity in Wuxi and Singapore.
- Abzena: ADC-focused CDMO with ThioBridge site-specific conjugation up to 80% single-DAR homogeneity.
- Piramal Pharma Solutions: commercial ADC conjugation capacity in Grangemouth, UK; multiple approved-product supply agreements.
- Sartorius (Polyplus): supplier of bioconjugation chemistry, DAR analytics, and conjugation-ready antibody handling for ADC developers.
- Thermo Fisher (Patheon) ADC services: integrated small-molecule drug-linker + biologics + fill-finish under one CDMO.
Frequently asked questions
What is the difference between mAb, bispecific antibody, and ADC manufacturing?
How does bispecific antibody titer compare to standard mAb titer in CHO?
How much does mAb manufacturing cost per gram compared to bispecific and ADC?
How many mAb, bispecific, and ADC products are FDA approved?
Why is bispecific antibody purification more complex than mAb purification?
What is the drug-to-antibody ratio (DAR) in ADC manufacturing and why does it matter?
Can the same CHO cell line make a mAb, a bispecific, and an ADC?
When should I choose bispecific over mAb or ADC for a new programme?
Resources and references
- Gong S, Wu C. Efficient production of bispecific antibodies — optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin. Antibody Therapeutics, 2023 — peer-reviewed demonstration that adjusting chain #2 expression ratio drives titer up to ~5 g/L at 97% purity for a bispecific format.
- BioProcess International — Development and Manufacture of Therapeutic Bispecific Antibodies — industry review covering knobs-into-holes, CrossMab, DuoBody formats and the 16-way / 12.5%-correct chain-pairing problem. Cites Merus titers of 1.0–1.5 g/L at 60–75% downstream yield.
- Biopharm Services. Antibody-Drug Conjugates Aren't Too Expensive — Cost of Manufacture Analysis — cost-of-goods model reporting ADC COGS at $499.70/g in an integrated facility and $777.50/g in a dedicated conjugation facility, with drug-linker at $4,000/g baseline.
- BioProcess International — Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates — industry publication on cysteine and site-specific conjugation chemistries, DAR control, and containment requirements for ADC manufacturing suites.